Literature DB >> 14101065

"MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE.

W W ZUELZER.   

Abstract

Keywords:  AGRANULOCYTOSIS; BONE MARROW EXAMINATION; CHILD; LEUKOCYTE COUNT; LYMPHADENITIS; PHAGOCYTOSIS; PHOTOMICROGRAPHY; POLYSACCHARIDES, BACTERIAL; PYROGENS

Mesh：

Substances：

Year:  1964        PMID： 14101065     DOI： 10.1056/NEJM196404022701402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  43 in total

1.  The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

Authors:  David C Dale; Audrey Anna Bolyard; Merideth L Kelley; Ernest C Westrup; Vahagn Makaryan; Andrew Aprikyan; Brent Wood; Frank J Hsu
Journal:  Blood       Date:  2011-08-11       Impact factor: 22.113

2.  WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

Authors:  Toshinao Kawai; Uimook Choi; Lanise Cardwell; Suk See DeRavin; Nora Naumann; Narda L Whiting-Theobald; Gilda F Linton; Jaehyun Moon; Philip M Murphy; Harry L Malech
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

3.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

4.  A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.

Authors:  Alessandra Handisurya; Christina Schellenbacher; Bärbel Reininger; Frieder Koszik; Philipp Vyhnanek; Andreas Heitger; Reinhard Kirnbauer; Elisabeth Förster-Waldl
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

Review 5.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

6.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

7.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

8.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

Review 9.  Genetic insights into congenital neutropenia.

Authors:  Christoph Klein; Karl Welte
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 10.  Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestations.

Authors:  Dominique C Pichard; Alexandra F Freeman; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2015-09       Impact factor: 11.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.